✦ LIBER ✦

Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up

✍ Scribed by Guerin, Mathilde; Salem, Naji; Walz, Jochen; Dermeche, Slimane; Gravis, Gwenaelle

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term safety of sorafenib in advance

✍ Thomas E. Hutson; Joaquim Bellmunt; Camillo Porta; Cezary Szczylik; Michael Stae 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 260 KB

399 Pathological changes after primary c

✍ C. Falo; A. Moreno; E. Arriola; M. Varela; B. Lloveras; E. Benito; A. Guma 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

473 Interleukin 2 (RIL2) in the treatmen

✍ K.H.M. Rowley; D. Mort; C.W. Keen; M.D. Mason 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Response to Sorafenib After Sunitinib-In

✍ Michael K. K. Wong; Anthony Jarkowski III 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

The significance of a 21 kDa protein ser

✍ Epelbaum, R; Moskovitz, B; Segal, R; Mekori, T; Nativ, O; Shalitin, C 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Cancer-free survival and local tumor con

✍ Forauer, Andrew R.; Dewey, Benjamin J.; Seigne, John D. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 735 KB